For research use only. Not for therapeutic Use.
Ulimorelin (Cat.No:I009945), also known as TZP-101, is a GHS receptor agonist potentially for the treatment of postoperative ileus and gastrointestinal disorders. TZP-101 accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. TZP-101 relieves gastroparesis associated with severe nausea and vomiting. TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type.
| Catalog Number | I009945 |
| CAS Number | 842131-33-3 |
| Synonyms | Ulimorelin; TZP-101; TZP 101; TZP101.;(2R,5S,8R,11R)-5-cyclopropyl-11-(4-fluorobenzyl)-2,7,8-trimethyl-4,5,7,8,10,11,13,14,15,16-decahydro-2H-benzo[q][1]oxa[4,7,10,13]tetraazacyclooctadecine-6,9,12(3H)-trione |
| Molecular Formula | C30H39FN4O4 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (7R,10R,13S,16R)-13-cyclopropyl-7-[(4-fluorophenyl)methyl]-10,11,16-trimethyl-17-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-6,9,12-trione |
| InChI | InChI=1S/C30H39FN4O4/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36)/t19-,20-,25-,27+/m1/s1 |
| InChIKey | WGYPAJVJMXQXTR-ABNZCKJZSA-N |
| SMILES | CC1CNC(C(=O)N(C(C(=O)NC(C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4 |
| Reference | </br>1:Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. Broad J, Callaghan B, Sanger GJ, Brock JA, Furness JB.Eur J Pharmacol. 2015 Apr 5;752:34-9. doi: 10.1016/j.ejphar.2015.02.005. Epub 2015 Feb 14. PMID: 25687251 </br>2:The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. Pustovit RV, Callaghan B, Kosari S, Rivera LR, Thomas H, Brock JA, Furness JB.Neurogastroenterol Motil. 2014 Feb;26(2):264-71. doi: 10.1111/nmo.12259. Epub 2013 Nov 7. PMID: 24304447 Free Article</br>3:Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials. Shaw M, Pediconi C, McVey D, Mondou E, Quinn J, Chamblin B, Rousseau F.Dis Colon Rectum. 2013 Jul;56(7):888-97. doi: 10.1097/DCR.0b013e31829196d0. PMID: 23739196 </br>4:Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. Hoveyda HR, Marsault E, Gagnon R, Mathieu AP, Vézina M, Landry A, Wang Z, Benakli K, Beaubien S, Saint-Louis C, Brassard M, Pinault JF, Ouellet L, Bhat S, Ramaseshan M, Peng X, Foucher L, Beauchemin S, Bhérer P, Veber DF, Peterson ML, Fraser GL.J Med Chem. 2011 Dec 22;54(24):8305-20. doi: 10.1021/jm2007062. Epub 2011 Nov 22. PMID: 22106937 </br>5:Ghrelin agonist TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type: covariate analysis of phase 2 data. Bochicchio G, Charlton P, Pezzullo JC, Kosutic G, Senagore A.World J Surg. 2012 Jan;36(1):39-45. doi: 10.1007/s00268-011-1335-9. PMID: 22072430 Free PMC Article |
